<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Genet Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Genet. Med</journal-id>
<journal-title-group>
<journal-title>Genetics in Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1098-3600</issn>
<issn pub-type="epub">1530-0366</issn>
<publisher>
<publisher-name>Nature Publishing Group US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32366965</article-id>
<article-id pub-id-type="pmc">7394879</article-id>
<article-id pub-id-type="publisher-id">815</article-id>
<article-id pub-id-type="doi">10.1038/s41436-020-0815-4</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Brief Communication</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>De novo variants of <italic>NR4A2</italic> are associated with neurodevelopmental disorder and epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Singh</surname>
<given-names>Sakshi</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gupta</surname>
<given-names>Aditi</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zech</surname>
<given-names>Michael</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sigafoos</surname>
<given-names>Ashley N.</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Clark</surname>
<given-names>Karl J.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dincer</surname>
<given-names>Yasemin</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="Aff7">7</xref>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wagner</surname>
<given-names>Matias</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Humberson</surname>
<given-names>Jennifer B.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Green</surname>
<given-names>Sarah</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>van Gassen</surname>
<given-names>Koen</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brandt</surname>
<given-names>Tracy</given-names>
</name>
<degrees>PhD FACMG</degrees>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schnur</surname>
<given-names>Rhonda E.</given-names>
</name>
<degrees>MD FACMG</degrees>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Millan</surname>
<given-names>Francisca</given-names>
</name>
<degrees>MD FACMG</degrees>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Si</surname>
<given-names>Yue</given-names>
</name>
<degrees>MD PhD</degrees>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mall</surname>
<given-names>Volker</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff7">7</xref>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Winkelmann</surname>
<given-names>Juliane</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff4">4</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
<xref ref-type="aff" rid="Aff13">13</xref>
<xref ref-type="aff" rid="Aff14">14</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gavrilova</surname>
<given-names>Ralitza H.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff15">15</xref>
<xref ref-type="aff" rid="Aff16">16</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Klee</surname>
<given-names>Eric W.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
<xref ref-type="aff" rid="Aff15">15</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Engleman</surname>
<given-names>Kendra</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="Aff17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Safina</surname>
<given-names>Nicole P.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff17">17</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Slaugh</surname>
<given-names>Rachel</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="Aff18">18</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bryant</surname>
<given-names>Emily M.</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="Aff19">19</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Wen-Hann</given-names>
</name>
<degrees>BMBS</degrees>
<xref ref-type="aff" rid="Aff20">20</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Granadillo</surname>
<given-names>Jorge</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff18">18</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Misra</surname>
<given-names>Sunita N.</given-names>
</name>
<degrees>MD PhD</degrees>
<xref ref-type="aff" rid="Aff19">19</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schaefer</surname>
<given-names>G. Bradley</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Towner</surname>
<given-names>Shelley</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brilstra</surname>
<given-names>Eva H.</given-names>
</name>
<degrees>MD PhD</degrees>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7749-182X</contrib-id>
<name>
<surname>Koeleman</surname>
<given-names>Bobby P. C.</given-names>
</name>
<degrees>PhD</degrees>
<address>
<email>b.p.c.koeleman@umcutrecht.nl</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000090126352</institution-id><institution-id institution-id-type="GRID">grid.7692.a</institution-id><institution>Department of Genetics, </institution><institution>University Medical Centre Utrecht, </institution></institution-wrap>Utrecht, The Netherlands </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution>Center for Individualized Medicine, Mayo Clinic, </institution></institution-wrap>Rochester, MN USA </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution>Department of Health Sciences Research, </institution><institution>Mayo Clinic, </institution></institution-wrap>Rochester, MN USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0483 2525</institution-id><institution-id institution-id-type="GRID">grid.4567.0</institution-id><institution>Institut für Neurogenomik, Helmholtz Zentrum München, </institution></institution-wrap>Munich, Germany </aff>
<aff id="Aff5"><label>5</label>Institut für Humangenetik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution>Department of Biochemistry and Molecular Biology, </institution><institution>Mayo Clinic, </institution></institution-wrap>Rochester, MN USA </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000000123222966</institution-id><institution-id institution-id-type="GRID">grid.6936.a</institution-id><institution>Lehrstuhl für Sozialpädiatrie, Technische Universität München, </institution></institution-wrap>Munich, Germany </aff>
<aff id="Aff8"><label>8</label>Zentrum für Humangenetik und Laboratoriumsdiagnostik (MVZ), Martinsried, Germany </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0000 9136 933X</institution-id><institution-id institution-id-type="GRID">grid.27755.32</institution-id><institution>Department of Pediatrics, </institution><institution>University of Virginia, </institution></institution-wrap>Charlottesville, VA USA </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 4687 1637</institution-id><institution-id institution-id-type="GRID">grid.241054.6</institution-id><institution>Section of Genetics and Metabolism, </institution><institution>University of Arkansas for Medical Sciences, </institution></institution-wrap>Little Rock, AR USA </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.428467.b</institution-id><institution>GeneDx, </institution></institution-wrap>Gaithersburg, MD USA </aff>
<aff id="Aff12"><label>12</label>kbo-Kinderzentrum München, Munich, Germany </aff>
<aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000000123222966</institution-id><institution-id institution-id-type="GRID">grid.6936.a</institution-id><institution>Lehrstuhl für Neurogenetik, Technische Universität München, </institution></institution-wrap>Munich, Germany </aff>
<aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.452617.3</institution-id><institution>Munich Cluster for Systems Neurology, SyNergy, </institution></institution-wrap>Munich, Germany </aff>
<aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution>Departments of Clinical Genomics and Neurology, </institution><institution>Mayo Clinic, </institution></institution-wrap>Rochester, MN USA </aff>
<aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0459 167X</institution-id><institution-id institution-id-type="GRID">grid.66875.3a</institution-id><institution>Department of Neurology, </institution><institution>Mayo Clinic, </institution></institution-wrap>Rochester, MN USA </aff>
<aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2179 926X</institution-id><institution-id institution-id-type="GRID">grid.266756.6</institution-id><institution>Division of Clinical Genetics, Children’s Mercy Kansas City, University of Missouri Kansas City School of Medicine, </institution></institution-wrap>Kansas city, MO USA </aff>
<aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2355 7002</institution-id><institution-id institution-id-type="GRID">grid.4367.6</institution-id><institution>Division of Genetics and Genomic Medicine, Department of Pediatrics, </institution><institution>Washington University School of Medicine, </institution></institution-wrap>St. Louis, MO USA </aff>
<aff id="Aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0388 2248</institution-id><institution-id institution-id-type="GRID">grid.413808.6</institution-id><institution>Ann &amp; Robert H. Lurie Children’s Hospital, Epilepsy Center, </institution></institution-wrap>Chicago, IL USA </aff>
<aff id="Aff20"><label>20</label>Division of Genetics and Genomics, Department of Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>5</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>5</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2020</year>
</pub-date>
<volume>22</volume>
<issue>8</issue>
<fpage>1413</fpage>
<lpage>1417</lpage>
<history>
<date date-type="received">
<day>4</day>
<month>12</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>16</day>
<month>4</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>4</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<sec>
<title>Purpose</title>
<p id="Par1">This study characterizes the clinical and genetic features of nine unrelated patients with de novo variants in the <italic>NR4A2</italic> gene.</p>
</sec>
<sec>
<title>Methods</title>
<p id="Par2">Variants were identified and de novo origins were confirmed through trio exome sequencing in all but one patient. Targeted RNA sequencing was performed for one variant to confirm its splicing effect. Independent discoveries were shared through GeneMatcher.</p>
</sec>
<sec>
<title>Results</title>
<p id="Par3">Missense and loss-of-function variants in <italic>NR4A2</italic> were identified in patients from eight unrelated families. One patient carried a larger deletion including adjacent genes. The cases presented with developmental delay, hypotonia (six cases), and epilepsy (six cases). De novo status was confirmed for eight patients. One variant was demonstrated to affect splicing and result in expression of abnormal transcripts likely subject to nonsense-mediated decay.</p>
</sec>
<sec>
<title>Conclusion</title>
<p id="Par4">Our study underscores the importance of <italic>NR4A2</italic> as a disease gene for neurodevelopmental disorders and epilepsy. The identified variants are likely causative of the seizures and additional developmental phenotypes in these patients.</p>
</sec>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>
<italic>NR4A2</italic>
</kwd>
<kwd>epilepsy</kwd>
<kwd>seizures</kwd>
<kwd>neurodevelopmental disorder</kwd>
<kwd>developmental disorder</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© American College of Medical Genetics and Genomics 2020</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>INTRODUCTION</title>
<p id="Par5">The <italic>NR4A2</italic> gene encodes a steroid–thyroid hormone–retinoid receptor that acts as a nuclear receptor (NR) transcription factor. The NR transcription factors play a regulatory role in various aspects of mammalian physiology such as neuronal development, inflammation, carcinogenesis, and memory formation. <italic>NR4A2</italic> is required for development, function, and neurotransmission of dopaminergic neurons.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup></p>
<p id="Par6">The <italic>NR4A2</italic> protein consists of two main domains: a DNA binding domain (DBD) and a ligand binding domain (LBD). The DBD is a highly conserved domain containing two C4 type zinc fingers that bind to specific motifs in DNA hormone response elements, and is connected to the C-terminal LBD via a linker region. The NR4A2 protein functions by binding small molecule ligands within conserved ligand binding patches located in the hydrophobic core of the LBD.<sup><xref ref-type="bibr" rid="CR2">2</xref></sup> Ligand binding induces a conformational change in the LBD leading to changes in interaction of nuclear receptor coregulators and other proteins. This alters chromatin structure and gene expression and, therefore, up and down regulation of target genes. A mutated gene may encode for a misfolded protein, dysfunctional ligand binding pocket, or dysfunctional DNA binding.</p>
<p id="Par7">Haploinsufficiency of the <italic>NR4A2</italic> gene caused by heterozygous chromosomal deletions was previously associated with a neurodevelopmental disorder with high penetrance, suggesting that heterozygous loss of <italic>NR4A2</italic> is autosomal dominant.<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>
<italic>NR4A2</italic> knockout in midbrain dopaminergic neurons of adult mice has shown to result in neuronal degeneration and impaired motor function.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Various polymorphisms in <italic>NR4A2</italic> have been associated with disorders related to dopaminergic dysfunction such as Parkinson disease, schizophrenia, manic depression, and autism spectrum disorder.<sup><xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref></sup> To our knowledge, there is only one previous report of a variant of <italic>NR4A2</italic> (NM_006186.3:c.327dup, p.S110Vfs*2) associated with epilepsy.<sup><xref ref-type="bibr" rid="CR7">7</xref></sup></p>
<p id="Par8">Here we report nine patients with variants in <italic>NR4A2</italic> and developmental delay/intellectual disability with or without epilepsy.</p>
</sec>
<sec id="Sec2" sec-type="materials|methods">
<title>MATERIALS AND METHODS</title>
<p id="Par9">Informed consent for genetic testing was obtained from all patients and parents included in the present study. The consent and protocols were approved by the respective institutional ethical review boards (University Medical Centre Utrecht, Mayo Clinic, Children’s Mercy Kansas City, Technical University of Munich, University of Arkansas for Medical Sciences, University of Virginia, Washington University School of Medicine, Boston Children’s Hospital, Ann &amp; Robert H. Lurie Children’s Hospital). All patients underwent exome sequencing; however, the variant identified in patient 2 was detected using a targeted exome analysis for neurodevelopmental genes. The deletion observed in patient 9 was detected by comparative genome hybridization using an Agilent 180K oligoarray. The microdeletion was verified by fluorescence in situ hybridization (FISH). All other cases were analyzed using the complete exome (Supplementary <xref ref-type="media" rid="MOESM1">information</xref>). By sharing through GeneMatcher,<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> we discovered other patients harboring variants in the <italic>NR4A2</italic> gene (patients 2, 4, 5, 7). For these patients, exome sequencing was performed at GeneDx (Gaithersburg, MD, USA) using the Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA) or the IDT xGen Exome Research Panel v1.0. The general assertion criteria for variant classification are publicly available on the GeneDx ClinVar submission page (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/">http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/</ext-link>). All variants identified in patients tested at GeneDx were reported as variants of uncertain significance in accordance with American College of Medical Genetics and Genomics (ACMG) criteria.<sup><xref ref-type="bibr" rid="CR9">9</xref></sup></p>
<p id="Par10">Variants were annotated based on <italic>NR4A2</italic> transcript NM_006186.3. De novo status of the variant was confirmed by exome sequencing or Sanger sequencing of parental samples. In silico tools MaxEntScan, NNSPLICE, and Human Splicing Factor predicted altered splicing and potential loss of function (LoF). Targeted RNA sequencing was done using blood-derived RNA of patient 2 to examine the functional consequences of the variant on splicing. Altered splicing was confirmed by reverse transcription polymerase chain reaction (RT-PCR) (details are in Supplementary Information Figures <xref ref-type="media" rid="MOESM1">S1</xref> and <xref ref-type="media" rid="MOESM1">S2</xref>). Plot Protein and RStudio v1.1.463 were used to visualize the variants in Fig. <xref ref-type="fig" rid="Fig1">1</xref>. Predicted domain architecture information for the corresponding amino acids in the protein was retrieved from databases SMART, Prosite, InterPro, and Pfam.<fig id="Fig1"><label>Fig. 1</label><caption><title>Schematic view of the distribution of pathogenic variants in <italic>NR4A2</italic>.</title><p>(<bold>a</bold>) Transcript description and locations (marked by circles) of the variants found in <italic>NR4A2</italic> gene. (<bold>b</bold>) Predicted effects (blue dots) of the pathogenic variants on NR4A2 protein sequence. The c.327dup,p.S110Vfs*2 variant was published previously.<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p></caption><graphic id="d30e887" xlink:href="41436_2020_815_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec3" sec-type="results">
<title>RESULTS</title>
<p id="Par11">We report a case series of nine patients with novel variants in <italic>NR4A2</italic>, including eight patients with a confirmed de novo variant, and one patient with a larger deletion encompassing <italic>NR4A2</italic>. The patients (five females, four males; mean age 12.4 years, age range 2–43 years, at the time of inclusion in current study) show heterogeneous phenotypes (detailed phenotypes are given in online Supplementary <xref ref-type="media" rid="MOESM1">information</xref>). Their neurodevelopmental phenotypes are characterized by delayed psychomotor development (9/9), which was initially normal in two patients. Individuals presented with varying levels (mild to severe) of intellectual disability (ID)/developmental delay (DD). Other features include epilepsy (6/9), speech/language impairment (5/9), behavioral problems (5/9), and movement disorder/hypotonia (8/9). Patients presented with variable epilepsy phenotype, including rolandic epilepsy, generalized encephalopathy, West syndrome, and infantile spasms. One patient showed epileptoform activity and photosensitivity on electroencephalogram (EEG). Seizure type included tonic clonic, generalized, absence, and focal seizures. Seizures remained refractory in two patients and the remaining four became seizure-free on appropriate antiepileptic drugs. Behavioral problems included autism, attention deficit–hyperactivity disorder, hyperactivity, anxiety, and hyposensitivity. Two patients had ataxia. There was no apparent genotype–phenotype correlation.</p>
<sec id="Sec4">
<title>Genetic results</title>
<p id="Par12">We identified eight patients with intragenic <italic>NR4A2</italic> variants and one patients carrying a larger deletion including <italic>NR4A2</italic>. Variants were not present in ExAC and gnomAD. De novo occurrence of the variants was confirmed for eight of these patients. The origin of the variant in patient 5 could not be confirmed due to unavailability of the father, but it was not maternal. Five patients had missense variants, one had a microdeletion, and three had nonsense or frameshift variants leading to a premature stop codon (Table <xref ref-type="table" rid="Tab1">1</xref>, Fig. <xref ref-type="fig" rid="Fig1">1</xref>). Four missense variants and one splice-acceptor site variant (c.839G&gt;A, p.C280Y; c.914G&gt;A, p.C305Y; c.857T&gt;C, p.F286S; c.968G&gt;T, p.C323F; c.865-1_865delGCinsAAAAAGGAGT) were located in the DBD of the protein that may affect DNA binding of the transcription factor. Patient 4 carried a missense variant (c.1175A&gt;G, p.D392G) affecting a hinge region without any secondary structure in the LBD. Patient 5 had a nonsense variant (c.1576G&gt;T, p.E526*) in the LBD, introducing premature termination. All missense variants were located in a gene region that is enriched for pathogenic variants across the <italic>NR4A2</italic> gene family (see Supplementary Figure <xref ref-type="media" rid="MOESM1">S4</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Clinical phenotypes of patients with heterozygous de novo and putative de novo <italic>NR4A2</italic> variants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>Variant (NM_006186.3)</th><th>Inheritance</th><th>Protein domain/region</th><th>Seizures</th><th>Age, years/sex/age at seizure onset</th><th>Developmental delay</th><th>Speech and language impairment</th><th>Motor delay</th><th>Intellectual disability</th><th>Behavioral problems</th><th>MRI findings</th><th>Neurologic examination findings</th><th>Other</th></tr></thead><tbody><tr><td>1</td><td>c.839G&gt;A, p.C280Y</td><td>De novo</td><td>ZnF_C4 domain, DNA binding domain</td><td>Yes</td><td>15/F/6.5 years</td><td>Global</td><td>NA</td><td>NA</td><td>Severe</td><td>Autism</td><td>Normal</td><td>Normal</td><td>Sleeping difficulties</td></tr><tr><td>2</td><td>c.865-1_865delGCinsAAAAAGGAGT, p.?</td><td>De novo</td><td>ZnF_C4 domain, DNA binding domain</td><td>Yes</td><td>12/M/10 years</td><td>Global</td><td>Yes</td><td>Yes</td><td>Mild</td><td>Hyperactivity, anxiety</td><td>Normal</td><td>Mild hypotonia</td><td>EDS hypermobility</td></tr><tr><td>3</td><td>c.914G&gt;A, p.C305Y</td><td>De novo</td><td>ZnF_C4 domain, DNA binding domain</td><td>Yes</td><td>9/F/NA</td><td>Moderate</td><td>NA</td><td>NA</td><td>Mild to moderate</td><td>NA</td><td>Gliosis</td><td>Choreoathetoid movements, dystonia, ataxic gait</td><td>NA</td></tr><tr><td>4</td><td>c.1175A&gt;G, p.D392G</td><td>De novo</td><td>Hinge region</td><td>Yes</td><td>3/F/5 months</td><td>Global</td><td>NA</td><td>NA</td><td>Severe</td><td>No</td><td>Moderate cerebellar atrophy</td><td>Severe hypotonia, feeding difficulties, dystonia</td><td>None</td></tr><tr><td>5</td><td>c.1576G&gt;T, p.E526*</td><td>NA</td><td>HOLI, ligand binding domain</td><td>No</td><td>5/M/Never</td><td>Global</td><td>Yes</td><td>Yes</td><td>Mild</td><td>Attachment disorder, hyposensitivity</td><td>NA</td><td>Mild hypotonia, no movement disorder</td><td>No</td></tr><tr><td>6</td><td>c.325dupC, p.Q109Pfs*3</td><td>De novo</td><td>N-terminal regulatory domain</td><td>Yes</td><td>2/M/6 months</td><td>Global</td><td>Yes</td><td>Yes</td><td>NA</td><td>Sensory sensitivity</td><td>Pontine hypoplasia, ventriculomegaly</td><td>Severe hypotonia, feeding difficulties</td><td>Facial dysmorphism, sleep disordered breathing</td></tr><tr><td>7</td><td>c.857T&gt;C, p.F286S</td><td>De novo</td><td>ZnF_C4 domain, DNA binding domain</td><td>No</td><td>4/F/Never</td><td>Global</td><td>Yes</td><td>Yes</td><td>Moderate</td><td>No</td><td>Normal</td><td>Hypotonia</td><td>Mild joint hypermobility, shagreen spot and hypopigmented spot</td></tr><tr><td>8</td><td>c.968G&gt;T, p.C323F</td><td>De novo</td><td>ZnF_C4 domain, DNA binding domain</td><td>No</td><td>19/F/Never</td><td>Global</td><td>Yes</td><td>Yes</td><td>Moderate to severe</td><td>No</td><td>Normal</td><td>Mild generalized hypotonia</td><td>Facial dysmorphism, joint hypermobility</td></tr><tr><td>9</td><td>arr[GRCh37]2q23.3q24.1(154790212_158488241)x1</td><td>De novo</td><td>NA</td><td>yes</td><td>43/M/13 years</td><td>Moderate</td><td>NA</td><td>NA</td><td>Moderate to severe</td><td>Hyperactivity, aggression</td><td>Enlarged cerebrospinal fluid spaces</td><td>Progressive ataxia in adulthood</td><td>No</td></tr></tbody></table><table-wrap-foot><p><italic>AED</italic> antiepileptic drug, <italic>EDS</italic> Ehlers–Danlos syndrome, <italic>EEG</italic> electroencephalogram, <italic>F</italic> female, <italic>M</italic> male, <italic>MRI</italic> magnetic resonance image, <italic>NA</italic> not assessed.</p></table-wrap-foot></table-wrap></p>
<p id="Par13">Patient 6 had a frameshift variant (c.325dup) in N-terminal regulatory domain introducing premature termination that is predicted to lead to nonsense-mediated decay (NMD) and LoF, similar to the previously published epilepsy patient (c.327dup).<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> Patient 9 carried a chromosomal microdeletion arr[GRCh37]2q23.3q24.1(154790212_158488241)x1 of size &gt;3.6 Mb (3698029 bp) encompassing the <italic>NR4A2</italic> gene. The deletion also covered ten flanking genes (<italic>KCNJ3</italic>, <italic>GPD2</italic>, <italic>GALNT5</italic>, <italic>ERMN</italic>, <italic>CYTIP</italic>, <italic>ACVR1C</italic>, <italic>ACVR1, UPP2</italic>, <italic>CCDC148</italic>, and <italic>PKP4</italic>).</p>
<p id="Par14">Various in silico tools predicted that the variant in patient 2 affects splicing that would lead to LoF. This was confirmed by RT-PCR (see Supplementary Figure <xref ref-type="media" rid="MOESM1">S2</xref>), which revealed altered splicing leading to aberrant transcripts with an out of frame skipping of exon 4 (130 nucleotides), which will potentially cause truncation and LoF through NMD.</p>
<p id="Par15">All variants had high predictive scores for a detrimental effect as predicted by SIFT, PolyPhen-2, and CADD scores. The <italic>NR4A2</italic> gene appears to be under a high selective strain and extremely intolerant to LoF variation as evidenced from its high probability of being LoF intolerant (pLI) score (1.0) and lower than expected missense variant counts (<italic>Z</italic>-score = 2.24), as observed in both ExAC and gnomAD. The haploinsufficiency score (HI score = 1.28%) shows this gene to be highly dosage sensitive. Therefore, intolerance to LoF can play an important role in the development of pathogenic phenotypes in patients.<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup></p>
</sec>
</sec>
<sec id="Sec5" sec-type="discussion">
<title>DISCUSSION</title>
<p id="Par16">We report nine patients with early onset epilepsy and/or a developmental disorder, of whom eight carried intragenic variants and on a larger deletion including <italic>NR4A2</italic>. Six of these patients with de novo <italic>NR4A2</italic> variants had epilepsy. The apparent intolerance to LoF and missense variation of <italic>NR4A2</italic> suggests that these variants are causing the phenotype in patients.<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup> In previous studies, haploinsufficiency of <italic>NR4A2</italic> has been implicated in a neurodevelopmental phenotype, including significant language impairment<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup> and ID.<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR7">7</xref></sup> These symptoms overlap with those observed in the patients studied here. We also observed language impairment in five of nine patients, which may be linked to the more prominent expression of <italic>NR4A2</italic> in the superior temporal gyrus (STG), a brain region linked to language development.<sup><xref ref-type="bibr" rid="CR13">13</xref></sup></p>
<p id="Par17">Regardless of the similarities among these nine patients, the underlying explanations for the phenotypes of patient 4 and patient 9 may be different. Patient 4 had a deceased sibling with similar phenotype. Therefore, the de novo variant detected in patient 4 may not explain the full phenotype, and another cause, as well as germline mosaicism, should be considered. For patient 9 the microdeletion also affected ten other genes that could have contributed to the clinical features. For example, <italic>KCNJ3</italic>, also deleted in this patient, encodes for subunit G-protein activated inward rectifier potassium channel 1. Alterations in the function of this potassium channel subunit have been associated with epilepsy.<sup><xref ref-type="bibr" rid="CR14">14</xref></sup></p>
<p id="Par18">It remains unclear how these variants of <italic>NR4A2</italic> contribute to the epileptogenesis. However, the physiologic role of <italic>NR4A2</italic> provides a clue toward the complex phenotypes of the patients with variants in this gene. NR4A2 is a known transcription factor and it binds to DNA as monomer or homodimer to promote constitutive activation of transcription.<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> It exerts concentration-dependent effects on target genes mediating distinct biological processes.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> The product of a mutated gene can be subjected to NMD leading to a misfolded protein, or a dysfunctional ligand binding pocket, or a dysfunctional DNA binding, resulting in impaired or loss of function. It is important to take into consideration that amino acid substitutions can also disrupt the conformation of the protein and such conformational changes might also compromise the function of <italic>NR4A2</italic>. A large case–control study of patients with neurodevelopmental disorders (such as autism spectrum disorder, DD, ID, and epilepsy) showed significant clustering of the de novo missense variants in cases at the protein level for 200 genes including <italic>NR4A2</italic>. In many cases, these de novo variants clustered in protein functional domains (such as zinc finger motifs, transmembrane domains, voltage sensors, and channel pores) relevant in the neurodevelopmental pathology. The de novo variants in zinc finger motifs were not present in public control databases. A clustering of variants in specific functional domains emphasized the importance of these de novo variants in characterizing pathogenic genes and functional domains.<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> The DBD of <italic>NR4A2</italic> contains two highly conserved C4 type zinc fingers that bind to specific motifs in DNA hormone response elements. Two of six patients with epilepsy have a missense variant in the DBD, whereas one patient has a missense variant in a hinge region with no secondary structure in the LBD and in N-terminal regulatory region of the protein. The two missense variants in the highly conserved DBD of NR4A2 may have resulted in impaired DNA binding ability. The other variants observed in patients are truncating variants and deletions, which taken together with the observed clustering of missense variants in a biological relevant protein domain strongly suggest that LoF is the underlying disease mechanism.</p>
<p id="Par19">It is well established that <italic>NR4A2</italic> is important for differentiation, survival and maintenance of dopaminergic neurons.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Furthermore, the dopamine activity transporter <italic>DAT</italic> gene has been associated with idiopathic absence epilepsy and seizures.<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> Various animal studies have investigated how the DAergic system is linked to epileptogenesis and neurodevelopmental dysfunction.<sup><xref ref-type="bibr" rid="CR1">1</xref></sup> Different subtypes of the dopamine receptors can act either as proconvulsant (D1-like receptor) or anticonvulsant (D2-like receptor). Physiological balance of DAergic activity at D1R and D2R can be decisive for complex neuromodulatory response for epileptogenesis.<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> The knockout or knockdown of <italic>NR4A2</italic> have resulted in poor motor function and lower number of DA neurons, lower levels of protein, and reduced DA at birth in midbrain.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> Studies of <italic>NR4A2</italic> heterozygosity in animal models have shown that the affected dopaminergic system is associated with altered locomotor behavior.<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> Furthermore, a crucial role of <italic>NR4A2</italic> in overall survival was supported by animal studies revealing its involvement in respiratory abnormality and lack of response to hypoxia. <italic>NR4A2</italic> is encoded by immediate early genes and has a significant role in development, neuroprotection, learning, and memory formation,<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> presenting a reasonable explanation for the associated ID among these patients. These studies indicate that variants in <italic>NR4A2</italic> can impair its various functions, and plausibly contribute to the seizure, neurodevelopmental, and global developmental phenotype observed in the described patients.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary information</title>
<sec id="Sec6">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41436_2020_815_MOESM1_ESM.docx"><caption><p>Supplementary Information</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn>
<p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
</fn-group>
<sec>
<title>Supplementary information</title>
<p>The online version of this article (10.1038/s41436-020-0815-4) contains supplementary material, which is available to authorized users.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This study was supported by the "friends of UMC &amp; Willemina Kinder Ziekenhuis" MING funds.</p>
</ack>
<notes id="FPar1" notes-type="COI-statement">
<title>Disclosure</title>
<p id="Par20">T.B., R.E.S., F.M., and Y.S. are employees of GeneDx. The other authors declare no conflicts of interest.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kadkhodaei</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Joodmardi</surname>
<given-names>E</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nurr1 Is required for maintenance of maturing and adult midbrain dopamine neurons</article-title>
<source/>J Neurosci
          <year>2009</year>
<volume>29</volume>
<fpage>15923</fpage>
<lpage>15932</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.3910-09.2009</pub-id>
<pub-id pub-id-type="pmid">20016108</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vera</surname>
<given-names>IMS</given-names>
</name>
<name>
<surname>Munoz-Tello</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Defining a canonical ligand-binding pocket in the orphan nuclear receptor Nurr1</article-title>
<source/>Structure
          <year>2019</year>
<volume>27</volume>
<fpage>66</fpage>
<lpage>77 e65</lpage>
<pub-id pub-id-type="doi">10.1016/j.str.2018.10.002</pub-id>
<pub-id pub-id-type="pmid">30416039</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lévy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grotto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mignot</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NR4A2 haploinsufficiency is associated with intellectual disability and autism spectrum disorder</article-title>
<source/>Clin Genet
          <year>2018</year>
<volume>94</volume>
<fpage>264</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="doi">10.1111/cge.13383</pub-id>
<pub-id pub-id-type="pmid">29770430</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>JJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between NR4A2 genetic variation and schizophrenia: a comprehensive systematic review and meta-analysis</article-title>
<source/>Neurosci Lett
          <year>2015</year>
<volume>598</volume>
<fpage>85</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1016/j.neulet.2015.05.018</pub-id>
<pub-id pub-id-type="pmid">25982322</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barkley</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Navia</surname>
<given-names>BA</given-names>
</name>
</person-group>
<article-title>Identification and characterization of human NR4A2 polymorphisms in attention deficit hyperactivity disorder</article-title>
<source/>Am J Med Genet B Neuropsychiatr Genet
          <year>2005</year>
<volume>133B</volume>
<fpage>57</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.b.30127</pub-id>
<pub-id pub-id-type="pmid">15635701</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feliciano</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Astrovskaya</surname>
<given-names>I</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exome sequencing of 457 autism families recruited online provides evidence for autism risk genes</article-title>
<source/>NPJ Genom Med
          <year>2019</year>
<volume>4</volume>
<fpage>19</fpage>
<pub-id pub-id-type="doi">10.1038/s41525-019-0093-8</pub-id>
<pub-id pub-id-type="pmid">31452935</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramos</surname>
<given-names>LLP</given-names>
</name>
<name>
<surname>Monteiro</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Sampaio</surname>
<given-names>LPB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Heterozygous loss of function of NR4A2 is associated with intellectual deficiency, rolandic epilepsy, and language impairment</article-title>
<source/>Clin Case Rep
          <year>2019</year>
<volume>7</volume>
<fpage>1582</fpage>
<lpage>1584</lpage>
<pub-id pub-id-type="doi">10.1002/ccr3.2260</pub-id>
<pub-id pub-id-type="pmid">31428396</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobreira</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schiettecatte</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hamosh</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>GeneMatcher: a matching tool for connecting investigators with an interest in the same gene</article-title>
<source/>Hum Mutat
          <year>2015</year>
<volume>36</volume>
<fpage>928</fpage>
<lpage>930</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22844</pub-id>
<pub-id pub-id-type="pmid">26220891</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richards</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bale</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>
<source/>Genet Med
          <year>2015</year>
<volume>17</volume>
<fpage>405</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1038/gim.2015.30</pub-id>
<pub-id pub-id-type="pmid">25741868</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lek</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Karczewski</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Minikel</surname>
<given-names>EV</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>
<source/>Nature.
          <year>2016</year>
<volume>536</volume>
<fpage>285</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1038/nature19057</pub-id>
<pub-id pub-id-type="pmid">27535533</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reuter</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Krumbiegel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schluter</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Ekici</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Reis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zweier</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Haploinsufficiency of NR4A2 is associated with a neurodevelopmental phenotype with prominent language impairment</article-title>
<source/>Am J Med Genet A
          <year>2017</year>
<volume>173</volume>
<fpage>2231</fpage>
<lpage>2234</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.38288</pub-id>
<pub-id pub-id-type="pmid">28544326</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leppa</surname>
<given-names>VM</given-names>
</name>
<name>
<surname>Kravitz</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>CL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rare inherited and de novo CNVs reveal complex contributions to ASD risk in multiplex families</article-title>
<source/>Am J Hum Genet
          <year>2016</year>
<volume>99</volume>
<fpage>540</fpage>
<lpage>554</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2016.06.036</pub-id>
<pub-id pub-id-type="pmid">27569545</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abrahams</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Tentler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Perederiy</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Oldham</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Coppola</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>DH</given-names>
</name>
</person-group>
<article-title>Genome-wide analyses of human perisylvian cerebral cortical patterning</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2007</year>
<volume>104</volume>
<fpage>17849</fpage>
<lpage>17854</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0706128104</pub-id>
<pub-id pub-id-type="pmid">17978184</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YW</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>SZ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>GIRK1-mediated inwardly rectifying potassium current suppresses the epileptiform burst activities and the potential antiepileptic effect of ML297</article-title>
<source/>Biomed Pharmacother
          <year>2018</year>
<volume>101</volume>
<fpage>362</fpage>
<lpage>370</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2018.02.114</pub-id>
<pub-id pub-id-type="pmid">29499411</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maira</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Martens</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Philips</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Drouin</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation</article-title>
<source/>Mol Cell Biol
          <year>1999</year>
<volume>19</volume>
<fpage>7549</fpage>
<lpage>7557</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.19.11.7549</pub-id>
<pub-id pub-id-type="pmid">10523643</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Michelhaugh</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Bouhamdan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Bannon</surname>
<given-names>MJ</given-names>
</name>
</person-group>
<article-title>The transcription factor NURR1 exerts concentration-dependent effects on target genes mediating distinct biological processes</article-title>
<source/>Front Neurosci
          <year>2011</year>
<volume>5</volume>
<fpage>135.</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2011.00135</pub-id>
<pub-id pub-id-type="pmid">22194714</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geisheker</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Heymann</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hotspots of missense mutation identify neurodevelopmental disorder genes and functional domains</article-title>
<source/>Nat Neurosci
          <year>2017</year>
<volume>20</volume>
<fpage>1043</fpage>
<lpage>1051</lpage>
<pub-id pub-id-type="doi">10.1038/nn.4589</pub-id>
<pub-id pub-id-type="pmid">28628100</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sander</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Berlin</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Ostapowicz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Samochowiec</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gscheidel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hoehe</surname>
<given-names>MR</given-names>
</name>
</person-group>
<article-title>Variation of the genes encoding the human glutamate EAAT2, serotonin and dopamine transporters and susceptibility to idiopathic generalized epilepsy</article-title>
<source/>Epilepsy Res
          <year>2000</year>
<volume>41</volume>
<fpage>75</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/S0920-1211(00)00120-0</pub-id>
<pub-id pub-id-type="pmid">10924870</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bensinger</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Tontonoz</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>A Nurr1 pathway for neuroprotection</article-title>
<source/>Cell
          <year>2009</year>
<volume>137</volume>
<fpage>26</fpage>
<lpage>28</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2009.03.024</pub-id>
<pub-id pub-id-type="pmid">19345183</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eells</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Lipska</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Yeung</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Misler</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Nikodem</surname>
<given-names>VM</given-names>
</name>
</person-group>
<article-title>Nurr1-null heterozygous mice have reduced mesolimbic and mesocortical dopamine levels and increased stress-induced locomotor activity</article-title>
<source/>Behav Brain Res
          <year>2002</year>
<volume>136</volume>
<fpage>267</fpage>
<lpage>275</lpage>
<pub-id pub-id-type="doi">10.1016/S0166-4328(02)00185-7</pub-id>
<pub-id pub-id-type="pmid">12385813</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>